Hepatitis C DAAs are commonly classified by the viral target they inhibit. Major classes include NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors. Clinical regimens typically combine agents from more than one class to suppress the virus at multiple points. This multi-target strategy improves effectiveness and helps reduce resistance risk. The specific class combination is selected based on the patient’s clinical profile and interaction screening.